A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: RIOCIGUAT

  • Pulmonary Hypertension due to PE: New Drug Approved

     Stephan Moll, MD writes… On Oct 8th, 2013 the FDA approved Adempas® (riociguat), a new oral drug to treat pulmonary hypertension.  The drug is a guanylate cyclase stimulator that leads to arteries dilatation. It is intended for: Patients with chronic thromboembolic pulmonary hypertension (CTEPH)